{"id":"W4253408104","doi":"10.1200/jco.2012.30.27_suppl.98","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Refractory (planetary science); Gastroenterology; Pertuzumab; Breast cancer; Cancer; Oncology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003692104,0.001876627,0.002186484,0.0005137106,0.0004793103,0.000932851,0.001430282,0.001226719,0.01129283],"category_scores_gemma":[0.001953475,0.0006227321,0.001882386,0.0005087386,0.0006833614,0.0006596498,0.0004038181,0.003465773,0.002038382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025692,"about_ca_system_score_gemma":0.001306361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007546275,"about_ca_topic_score_gemma":0.002457196,"domain_scores_codex":[0.9992548,0.0004421896,0.00004529874,0.00008476811,0.00006257129,0.0001104678],"domain_scores_gemma":[0.9984971,0.0003875505,0.0003306194,0.0001095972,0.0001003537,0.0005747132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8594188,0.0443111,0.005254168,0.001889193,0.002587134,0.0002741893,0.0001736729,0.001886282,0.02003851,0.0001765509,0.00987339,0.05411703],"study_design_scores_gemma":[0.6839676,0.2812131,0.02144762,0.0001287034,0.002018897,0.0003594251,0.00004858546,0.0005773423,0.004211299,0.0001114462,0.005887888,0.00002812018],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9420034,0.008439748,0.001667543,0.001233679,0.0003758552,0.01638531,0.01489084,0.0002913489,0.01471225],"genre_scores_gemma":[0.9557987,0.004762634,0.003147011,0.002495163,0.0004822717,0.007967799,0.01662811,0.0001051956,0.008613113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01129283,"threshold_uncertainty_score":0.03777832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.120029974007668,"score_gpt":0.4837508507159989,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}